TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01656122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir
Description: Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC
Description: Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
Study: NCT03242447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Practice Self-Regulation
Description: e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Health Group
Description: The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
Study: NCT04098588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEAST
Description: See Arm Description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Descriptive Feedback
Description: See Arm Description
Study: NCT01920113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine - remifentanil group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol - remifentanil group
Study: NCT01505088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg/mL Dexamethasone phosphate ophthalmic solution
Description: Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate (1%) Eyedrops
Description: Prednisolone acetate (1%) eyedrops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mM sodium citrate buffer solution
Description: Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Eyedrops
Description: Placebo Eyedrops
Study: NCT03586921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Group Intervention
Description: The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
Study: NCT01704157

Intervention type: DEVICE
Group type: OTHER
Intervention: Cryo-Touch III
Description: Study treatment at Day 0.
Study: NCT01853280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-methylfolate
Description: 15mg/day L-methylfolate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-Methylphenidate
Description: All subjects will be treated with open-label OROS-MPH

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OROS-Methylphenidate
Description: All subjects will be treated with open-label OROS-MPH

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg matched placebo comparator, with open-label OROS-Methylphenidate
Study: NCT01683812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Cup
Description: Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
Study: NCT03738228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study: NCT00333840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine (ARA-C)
Description: cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
Study: NCT03901651

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique
Description: Colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the standard colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with standard colonoscope and forward withdrawal technique
Description: A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location.
Study: NCT01975714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free bimatoprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free bimatoprost
Study: NCT00875264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-11981 (kinase inhibitor)
Description: Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
Study: NCT02293057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VOICES Group
Description: VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Girl Health Group
Description: The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
Study: NCT01232777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
Study: NCT03373071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR T cell
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment
Study: NCT01733784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induced central apneas
Study: NCT01529242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine + Prednisolone
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine + Betamethasone
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
Study: NCT04184544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improving of quality of care at health facility and outreach level
Description: Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improving of quality of care at health facility and outreach level
Description: Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
Study: NCT02221024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flushing with positive pressure
Description: Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flushing with positive pressure
Description: Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroClave ICU Medica

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroClave ICU Medica
Study: NCT03845777

Intervention type: DIAGNOSTIC_TEST
Intervention: Using Antiseptic solution
Description: Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
Study: NCT00074984

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fabrazyme (agalsidase beta)
Description: 1mg/kg Fabrazyme (agalsidase beta) every 2 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg/kg placebo intravenously every 2 weeks
Study: NCT03738228

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo standard of care image guided brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo standard of care image guided brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT00934557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius
Study: NCT02023593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study: NCT03738228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study: NCT04054362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein bound
Description: paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein bound
Description: paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
Study: NCT02236910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lu-DOTA-TATE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lu-DOTA-TATE
Study: NCT01955564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-3509a
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-3509a
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-3509a
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-3509a
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-3509a
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-3509a
Description: single dose
Study: NCT01436396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated dengue serotype 1, 2, 3, and 4 virus
Description: 0.5 mL, subcutaneous at age 12, 18, and 24 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine
Description: 0.5 mL subcutaneous in the deltoid at age 12 to 13 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella (MMR) vaccine
Description: 0.5 mL, subcutaneous at age 12 to 13 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugated Vaccine
Description: 0.5 mL, intramuscular at age 13 to 14 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Pediatric Vaccine
Description: 0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
Description: 0.5 mL, intramuscular at age 19 to 20 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated dengue serotype 1, 2, 3, and 4 virus
Description: 0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: 0.5 mL, subcutaneous at age 12 to 13 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (NaCl)
Description: 0.5 mL, subcutaneous at age 12 to 13 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella vaccine
Description: 0.5 mL, subcutaneous at age 13 to 14 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugated Vaccine
Description: 0.5 mL, intramuscular at age 13 to 14 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
Description: 0.5 mL, intramuscular at age 19 to 20 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Pediatric Vaccine
Description: 0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
Study: NCT02182739

Intervention type: DRUG
Intervention: Meloxicam
Description: tablets or injectable solution
Study: NCT01554436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Description: The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test
Study: NCT03855865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (prefilled syringe, weekly IV administration or oral daily).
Study: NCT01573260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Argentinean Tango classes
Description: Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simple pamphlet about the exercise in PD
Description: Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
Study: NCT00667160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus cream
Description: topical
Study: NCT02005731

Intervention type: DEVICE
Intervention: Low intensity linear focused shockwave device ('Renova')
Study: NCT03393364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Patients receive oxycodone for pain control after outpatient urologic surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Patients receive ketorolac for pain control after outpatient urologic surgery
Study: NCT01105416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prevention Intervention (BPI)
Description: Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ESC
Description: Enhanced standard care
Study: NCT00576784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone and glimepiride
Description: switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
Study: NCT01881035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal nerve denervation
Description: Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
Study: NCT02358330

Intervention type: OTHER
Intervention: EHR Enhanced Clinic Intervention
Description: The clinics assigned to the experimental condition will have EHR enhancements introduced.
Study: NCT00932139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture control
Description: First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture control
Description: First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture test
Description: First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture test
Description: First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
Study: NCT03956953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Dose 1 or Dose 2 on Day 1, and from Days 5-19'

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Dose 1 or Dose 2 on Day 1, and from Days 5-19'

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
Study: NCT04114942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constant Coach
Description: 20 weeks of didactic training and 10 weeks of internship, with coaching throughout.